|Inclusion Criteria:||1) Previous completion of a carfilzomib study within 90 days prior to first dose of extension study drug.|
2) Disease Assessments performed within 30 days prior to first dose of maintenance study drug.
3) Written informed consent in accordance with federal, local, and institutional guidelines
4) Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test, with a sensitivity of at least 50 mIU/mL, within 3 days prior to first dose of maintenance study drug.
5) Subjects must agree to adhere to the study visit schedule and other study requirements and receive outpatient treatment and laboratory monitoring at the institution that administers the drug.